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Abstract
Background: This study was designed to evaluate the population pharmacokinetics (popPK) of penicillin G
in patients with infective endocarditis and establish a dosage regimen based on pharmacokinetic data and
clinical outcome.
Method: Forty-six serum penicillin G samples from 25 individuals were analyzed using a nonlinear mixed-effects
model. popPK were estimated using a one-compartment model. We created a receiver operating characteristic
(ROC) curve for penicillin G efficacy and the ratio of its minimum concentration (Cmin)/minimum inhibitory
concentration (MIC). Simulations were used to optimize the penicillin G dosage regimen using this ratio.
Result: Estimated popPK were: CL (L/h) = 0.21 × creatinine clearance (CLcr) (mL/min), Vd (L) = 28.9. The areas
under the ROC curves were 0.87 for clinical efficacy. The cut-off value of penicillin G Cmin/MIC was 60. The
continuous administration of 1 million IU penicillin G/h was necessary to achieve a positive outcome for
patients with normal renal function (CLcr ≥ 60 mL/min).
Conclusion: Our findings suggest that population-based parameters are useful for evaluating penicillin G
pharmacokinetics and that an individualized dosage should be determined based on a described dosage regimen.
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Background
Penicillin G, discovered by Alexander Fleming in
1928, was the first antibiotic to be recognized. Penicil-
lin G is still used widely for the treatment of meningi-
tis, dermatomyositis, and infective endocarditis caused
by viridans group streptococci. Nevertheless, infective
endocarditis remains a disease with high morbidity
and with a mortality rate of 16–37.1 % [1–3]. The
2009 European Society of Cardiology guidelines recom-
mend 4 weeks of monotherapy with penicillin G or ceftri-
axone for infective endocarditis caused by susceptible
streptococci [4]. The efficacy of penicillin G correlates with
the percentage of time above the minimum inhibitory con-
centration (MIC) (TAM). In general, the therapeutic goal
for curing infections caused by gram-positive organisms is
an antimicrobial TAM of at least 30 % [5]. At a normal
penicillin G dosage of 4 million international units (IU) ad-
ministered intravenously every 4 h, a TAM of at least 30 %
has been reported to result in 100 % penicillin-susceptible
(penicillin MIC ≤ 0.125 mg/L) or intermediate penicillin-
resistant streptococci (MIC 0.125–2 mg/L). Therefore,
we do not believe this parameter is achievable for in-
fective endocarditis [6]. In general, the population
pharmacokinetics (popPK) of penicillin G are insuffi-
ciently known. Thus, the popPK of penicillin G were
analyzed in patients with infective endocarditis. We
also determined the relationship between the blood
concentrations of penicillin G and clinical outcomes.
Furthermore, effective initial dosing regimens for in-
fective endocarditis were determined according to our
popPK data.
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Clinical data were collected from patients treated with
penicillin G potassium (Meiji Seika Pharma Co. Ltd,
Tokyo, Japan) for suspected or documented infective
endocarditis at Kitasato University Hospital between
January 1997 and April 2013. The collected data in-
cluded age, gender, height, body weight (BW), alanine
aminotransferase (ALT), serum creatinine, creatinine
clearance (CLcr), isolated microorganisms, clinical
outcome, and serum concentrations of penicillin G.
CLcr was estimated from the serum creatinine level by
the Cockcroft-Gault method [7]. Failure of penicillin
G treatment was defined as persistence of fever and/or
bacteremia by the causative pathogen requiring a
change in antibiotic therapy, and infection-related
mortality within 30 days.
Blood samples were obtained from a brachial vein im-
mediately before and 2 or 3 h after administration of
penicillin G for determination of serum penicillin G
levels. Human subject procedures were approved by the
Ethics Committee of Kitasato University Hospital. In
addition, we obtained written informed consent from
each patient.
Assay of penicillin G concentrations
Blood samples were collected using serum-separator
tubes, centrifuged immediately at 3000 rpm for 10 min
at room temperature and the serum separated. Penicillin
G concentrations were measured using minor modifica-
tions of a high-performance liquid chromatography (HP
LC) method published previously [8]. The mobile phase
consisted of acetonitrile and 50 mM potassium phos-
phate buffer (1:1, v/v), adjusted to pH 5.0 at a flow rate
of 0.8 mL/min. Methanol (500 μL) was added to 200 μL
of serum. This mixture was vortexed immediately for
30 s and finally centrifuged at 15,000 rpm for 5 min at
room temperature. The supernatant was filtered and
20 μL injected into the HPLC. The lower limit of detec-
tion of penicillin G was 0.5 μg/mL. The coefficients of
variation for both intra- and inter-assay precision were
less than 10 %.
Pharmacokinetic calculations
Data analyses were performed with the nonlinear mixed
effects model program (version VI, level 1.0) developed
by Beal and Sheiner [9]. A one-compartment pharmaco-
kinetic model was employed using the ADVAN1 and
TRANS2 subroutines. The parameters of the structural
model were clearance (CL) and volume of distribution
(Vd). The first order conditional estimation method
was applied for modeling. Inter-individual variability of
the parameters was best explained by an exponential
error model (Pi = TV(Pi) × exp(ηi)) where Pi indicated
an individual value, TV(Pi) was the population value for
the parameters described in the equation, and ηi was
the random deviation of Pi from TV(Pi). The value of
ηi was assumed to be independent and distributed
normally with a mean of 0 and a variance of ω2. The re-
sidual (intra-individual) variability of the parameters
was also explained by a proportional error model
(Cobs,ij = Cpred,ij × (1 + εij)) where Cobs,ij and Cpred,ij
denote the jth observed and predicted concentrations
for the ith subject, respectively, and ε is a random intra-
individual error that is distributed normally with a
mean of 0 and variance σ2.
Covariate analysis
Covariance of the following variables was tested to im-
prove the popPK model: age, serum creatinine, CLcr,
BW, ALT, and gender. The influence of continuous
Table 1 Patient characteristics
Number of Patients 25
Gender (Male:Female) 16:9
Age (year) 54 ± 17a (21–83)b
Scr (mg/dL) 0.92 ± 0.56 (0.51–3.26)
CLcr (mL/min) 82.52 ± 33.29 (11–144)
ALT (IU/L) 26.80 ± 26.45 (4–106)
Weight (kg) 55.35 ± 33.31 (33–86.9)
Observation 46
PCG concentraion (μg/mL) 33.2 ± 45.2 (0.5–212.3)
Scr serum creatinine, CLcr creatinine clearance, ALT alanine aminotransferase
aMean ± standerd diviation
bRange





n = 21 n = 15 n = 6
Size of vegetation (mm) 11.7 ± 6.0 12.3 ± 6.3 9.8 ± 5.7
PCG MIC 0.11 ± 0.20 0.07 ± 0.02 0.21 ± 0.38
PCG trough serum
concentrations (μg/mL)
7.8 ± 9.0 10.1 ± 9.8 2.2 ± 1.2
Viridans group streptococci
species level not determined
4 1 3
streptococcus sanguis 5 2 3
streptococcus gordonii 4 4 0
streptococcus agalactiae 2 2 0
streptococcusmutans 1 1 0
streptococcus intermedius 2 2 0
streptococcus mitis 1 1 0
streptococcus oralis 1 1 0
streptococcus constellatus 1 1 0
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covariates on the pharmacokinetic parameter TV(P)
was modeled according to the following equations: TV
(P)=θp+θc× (covariance), andTV(P)=θp×θc(covariance).
Covariance showing a correlation with the pharmaco-
kinetic parameters was introduced into the model.
The significance of the influence of covariates was
evaluated by a change of −2 log likelihood (the mini-
mum value of the objective function: OBJ). An OBJ
decrease of more than 6.63 from the full model (χ2:
degree of freedom = 1, P < 0.01) was considered statis-
tically significant during the forward inclusion process.
The full model was structured by incorporating the signifi-
cant covariates, and the final model was developed by a
backward elimination method. When one covariate factor
was excluded from the full model, an OBJ that increased
more than 6.63 from the full model was considered statis-
tically significant.
Model evaluation
The adequacy of fitting was examined by plotting the
predicted versus the observed concentration of penicillin
G, the individual predicted concentration after each
Bayesian step versus observed concentration, and the
conditional weighted residual concentration versus the
predicted one. The accuracy and robustness of the final
model were assessed using the bootstrap method [10].
Bootstrap samples were generated by repeated random
sampling of the original data set. The size of each boot-
strap sample was the same as that of the original sample.
Two hundred bootstrap samples were constructed, and
the final model was determined by testing these samples
repeatedly. The mean parameter estimates obtained from
Fig. 1 Penicillin G minimum serum concentrations/MIC and logistic regression model for clinical outcomes (failure, 0; success, 1)
Fig. 2 Receiver operating characteristic curve for predicting clinical
efficacy using penicillin G minimum serum concentration/MIC
Table 3 Hypothesis testing for fixed effect model on penicillin
G pharmacokinetics
Fixed model OBJ −2.l.l.d p-value
CL = θ1 356.307
θ1 + θ2 × CLcr 239.004 117.303 <0.001
θ1 + θ2 × 1/sCr 280.388 75.919 <0.001
θ1 + θ2 × BW 323.407 32.9 <0.001
θ1 × θ2ALT (ALT > 40 = 0,ALT < 40 = 1) 337.037 19.27 <0.001
θ1 × θ2sex (Male = 1,Female = 0) 324.973 31.334 <0.001
θ1 × θ2Age (Age > 65 = 1,Age < 64 = 0) 347.699 8.608 <0.005
Vd = θ3
θ3 + θ4 × BW 356.307 0 N.S.
N.S not significant, CLcr creatinine clearance, ALT alanine aminotransferase,
BW body weight
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the replicates using normal calculations were compared
with those obtained from the original data set.
Target serum concentration of penicillin G in patients
with infective endocarditis
The relationship between the penicillin G Cmin/
MIC ratio and clinical outcome (clinical failure = 0,
clinical success = 1) was analyzed using a logistic re-
gression model. Statistical analyses were performed
using JMP statistical software (version 6.03; SAS Insti-
tute, Cary, NC, USA). Additionally, receiver operating
characteristic (ROC) curve analysis was performed to
determine the efficacy of a test by providing informa-
tion about both sensitivity and specificity at different
cut-off points. A two-tailed P value of less than 0.05
was considered significant. The MIC of penicillin G
was determined using the MicroScan WalkAway 96
plus (Beckman Coulter, Brea, CA, USA) fully auto-
matic bacterial system that conforms to the micro
dilution method according to the Clinical and Labora-
tory Standards Institute.
Table 4 Summary of results for the basic and final population
models
Basic model Final model
CL (L/h) = θ1 CL (L/h) = θ1 ×
CLcr (mL/min)
Vd (L) = θ2 Vd (L) = θ2
Parameter Mean 95 % CI Mean 95 % CI
θ1 8.09 6.75–9.42 0.21 0.173–0.246
θ2 39.1 34.0–44.2 28.9 24.0–33.7
Interindividual variability
ηCL 0.765 0.465–1.065 0.0835 0.0292–0.137
ηvd 0.217 0.135–0.298 0.104 0.094–0.115
Residual variability
ε 0.0643 0.0306–0.0979 0.0304 0.0269–0.0334
η, random variable, which is normally distributed with mean 0 and
variance ω2
ε, random error, which is normally distributed with mean 0 and variance σ2
CI confidence interval, CLcr creatinine clearance
Fig. 3 Relationship between observed penicillin serum concentrations (Cp) and predicted concentrations (PRED) (a), or individual predicted
concentrations after Bayesian fitting (IPRED) (b). Scatter plot of conditional weighted residuals (CWRES) versus predicted PRED is presented in (c)
Table 5 Final population pharmacokinetic parameters of
penicillin G
Parameter Estimate RSE (covariance
step)
95 % CI (bootstrap
method)
Population mean
CL (L/h) = θ1 × CLcr
(mL/min)
θ1 0.21 8.81 % 0.171–0.249
Vd (L) = θ2
θ2 28.9 8.58 % 23.4‐34.7
Interindividual
variability
ηCL 0.0835 33.1 % 0.0171‐0.1397
ηvd 0.104 5.22 % 0.0087–0.1203
Residual variability
ε 0.0304 5.85 % 0.0265–0.0342
η, random variable, which is normally distributed with mean 0 and
variance ω2
ε, random error, which is normally distributed with mean 0 and variance σ2
RSE relative standard error, CI confidence interval, CLcr creatinine clearance
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Determination of the dosing regimen
Pharmacokinetic simulations were performed to deter-
mine the optimal dosing regimen based on our popPK
data. Penicillin G concentrations were simulated for
1000 patients using the final popPK model. For the
assessment of efficacy, the percentage of patients that
achieved penicillin G Cmin/MIC ratios above 60 was
calculated for each data set. For the assessment of safety,
the percentage of patients that achieved penicillin G
peak concentrations below 100 μg/mL was calculated for
each data set. The MIC was fixed at 0.06 and 0.12 mg/L
because these MICs are seen frequently in our hospital.
Monte Carlo simulation was performed using Crystal
Ball 2000 software (Oracle, Redwood Shores, CA, USA).
Results
Patient characteristics are shown in Table 1. Serum con-
centrations of penicillin G were measured in a total of
25 patients treated with penicillin G for infective endo-
carditis. Viridans group streptococci were isolated in 21
of these patients, 15 of whom showed a positive re-
sponse to penicillin G (success) and 6 showed no re-
sponse (failure) (Table 2).
Figure 1 shows the relationship between penicillin G
Cmin/MIC and clinical outcome (failure = 0, success =
1). Penicillin G Cmin/MIC was a significant predictor of
the following clinical outcome equation: probability of a
positive clinical outcome = 1/{1 + exp(1.609–0.0524 × <
penicillin G Cmin/MIC>)}. Figure 2 shows the optimal
ROC curve for predicting clinical efficacy using the
penicillin G Cmin/MIC ratio. The area under the ROC
curve was 0.83 and the cut-off value of penicillin G
Cmin/MIC for clinical efficacy was 60 (sensitivity 68 %,
specificity 100 %).
The results from each covariate model are shown in
Table 3. CLcr, serum creatinine, BW, ALT, gender, and
Fig. 4 Probability of attaining targets above a penicillin minimum serum concentration/MIC ratio of 60 at CLcr ranging from 5 to 120 with MIC
fixed at (a) 0.06 or (b) 0.12 μg/mL
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age were significant covariates for the CL of penicillin G.
During backward deletion from the full model, CLcr
remained in the model and caused a significant increase
in the OBJ. Table 4 summarizes the popPK estimates
from the basic and final models. The final model was:
CL (L/h) = 0.21 × CLcr (mL/min), Vd (L) = 28.9. The co-
efficients of variation of the inter-individual variability
(ω2) of CL, Vd, and the residual variability (σ2) were
28.8, 32.4, and 17.4 %, respectively.
Assessment of the predictive performance of the final
model is presented in scatter plots of the observed ver-
sus the population-predicted concentrations (Fig. 3a),
and the individual-predicted concentrations of penicillin
G (Fig. 3b). Conditional weighted-residual concentration
versus the population predicted concentration is pre-
sented in Fig. 3c. These plots are distributed symmetrically
around the line of identity, indicating that the model de-
scribes the serum concentration of penicillin G adequately.
In the bootstrap analysis of the final model, 158 of 200
bootstraps showed successful results. The values of the
parameters used in the final model generated from the
bootstrap analysis were similar to those of the developed
model (Table 5).
A simulation was performed using the final model to
determine the optimal dosing regimen in patients with
renal impairment. Penicillin G concentrations were sim-
ulated for 1000 patients exhibiting CLcr ranging from 5
to 120 mL/min. The target was a Cmin/MIC value above
60 as estimated by Fig. 2. The simulation was performed
for dosages ranging from 0.5 million IU every 6 h to 4
million IU every 4 h, as well as 1 million IU/h (Fig. 4).
Figure 5 shows the typical initial dose of penicillin G for
MICs of 0.06 and 0.12 μg/mL in patients with various
CLcr based on the simulation experiments.
Discussion
This is the first popPK study of penicillin G that was
used to propose a dosing regimen. Although a three-
compartment model has been described for penicillin G
[11], we used a one-compartment model because our
sampling points for serum penicillin G levels were at the
trough and 2 or 3 h after administration of penicillin G,
and there were few data during the elimination phase.
As a result, CLcr was a significant covariant for the sys-
temic clearance of penicillin G that occurs through the
kidney [12, 13]. Dittert et al. reported that the Vd for
penicillin G was 33 L in healthy people [13]. This value
is very close to that obtained in our study (28.9 L). The
reported serum half-life of penicillin G in patients with
normal renal function ranged from 0.38 to 0.78 h [14,
15]. These values are very similar to our data (0.79 h)
calculated by keeping the CLcr fixed at 120 mL/min.
Predictions of the penicillin G concentrations were
made with the final regression model. The model ex-
hibited a good linear correlation between observations
and the individual predicted concentrations after the
Bayesian steps. The final model lacked bias on the re-
lationship between Figs. 3a, b. Specifically, the condi-
tional weighted residuals were acceptable to within
three standard deviations, which is generally recog-
nized as the criterion for no selection biases (Fig. 3c).
Therefore, we concluded that the final model had a
good predictive performance.
The logistic regression model (Fig. 1) and ROC curve
(Fig. 2) revealed a significant association between peni-
cillin G Cmin/MIC ratios and the therapeutic effect. The
threshold penicillin G Cmin/MIC ratio that led to clin-
ical success was above 60, the cut-off associated with
100 % probability of response to therapy. Figure 4 also
Fig. 5 Nomogram for the initial dosage of penicillin against viridans group streptococci
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showed the probability of success with a penicillin G
Cmin/MIC ratio above 60 and a penicillin G peak concen-
tration below 100 μg/mL. At this peak concentration, pa-
tients became comatose with continuous muscle jerking
[16]. García-Cabrera et al. reported infective endocarditis
with a mortality rate of 30 % [17]. Our data showed a
29 % failure rate of penicillin G treatment (6/21). Al-
though there were some patients with a positive response
to penicillin G whose penicillin G Cmin/MIC ratios were
lower than 60, patients whose values were over 60 all had
a positive response.
This regimen was used to determine the typical initial
dosage of penicillin G against viridans group strepto-
cocci in patients with various CLcr. The continuous
administration of 1 million IU/h at a MIC of 0.06 was
necessary to achieve therapeutic success against infective
endocarditis in patients with normal renal function
(CLcr > 60 mL/min). Continuous infusion of penicillin G
is recommended by the American Heart Association
guidelines [18]. Overall, the method described in this
project assured therapeutic efficacy in infective endo-
carditis with a negligible risk of neurotoxicity [19]. The
initial dosage regimen determined using our model will
be useful for patients with infective endocarditis caused
by Streptococcus spp. A prospective study using this
regimen will help determine the robustness and reli-
ability of our model.
Conclusion
This is the first popPK study of penicillin G that was
used to propose a dosing regimen. CLcr was a signifi-
cant covariant for the systemic clearance of penicillin
G. Additionally, the results showed that continuous ad-
ministration of 24 million units of penicillin G over
24 h was necessary to achieve a positive outcome for
patients with normal renal function (CLcr ≥ 60). Our
findings suggest that population-based parameters are
useful for evaluating penicillin G pharmacokinetics and
that an individualized dosage should be determined
based on a described dosage regimen.
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